Ocean Net Income From Continuing Ops from 2010 to 2024

OCEAW Stock   0.04  0  9.77%   
Ocean Biomedical Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, Ocean Biomedical Net Loss regression line of quarterly data had r-squared of  0.45 and coefficient of variation of (210.18). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-114.5 M
Current Value
-108.7 M
Quarterly Volatility
40.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ocean Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocean Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Selling General Administrative of 10.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 3.44 or Days Sales Outstanding of 0.0. Ocean financial statements analysis is a perfect complement when working with Ocean Biomedical Valuation or Volatility modules.
  
Check out the analysis of Ocean Biomedical Correlation against competitors.
For more information on how to buy Ocean Stock please use our How to Invest in Ocean Biomedical guide.

Latest Ocean Biomedical's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Ocean Biomedical over the last few years. It is Ocean Biomedical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocean Biomedical's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Ocean Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(19,365,609)
Coefficient Of Variation(210.18)
Mean Deviation30,327,450
Median(232,000)
Standard Deviation40,701,879
Sample Variance1656.6T
Range114.2M
R-Value(0.67)
Mean Square Error988.9T
R-Squared0.45
Significance0.01
Slope(6,076,150)
Total Sum of Squares23193T

Ocean Net Income From Continuing Ops History

2024-108.7 M
2023-114.5 M
2022-958.4 K
2021-62.3 M
2020-1.7 M

About Ocean Biomedical Financial Statements

Ocean Biomedical investors use historical fundamental indicators, such as Ocean Biomedical's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Ocean Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-114.5 M-108.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Ocean Stock Analysis

When running Ocean Biomedical's price analysis, check to measure Ocean Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocean Biomedical is operating at the current time. Most of Ocean Biomedical's value examination focuses on studying past and present price action to predict the probability of Ocean Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocean Biomedical's price. Additionally, you may evaluate how the addition of Ocean Biomedical to your portfolios can decrease your overall portfolio volatility.